Market Overview

Zogenix Secures FDA Approval For Resubmission Of Seizure Drug Application

Share:
Zogenix Secures FDA Approval For Resubmission Of Seizure Drug Application

Shares of the thinly traded, small-cap biotech Zogenix, Inc. (NASDAQ: ZGNX) were rallying Thursday.

What Happened

Zogenix, which focuses on developing rare disease therapies, said following the receipt of the minutes of a May 30 Type A meeting with the FDA, it plans to resubmit the NDA for Fintepla, its investigational asset for the treatment of seizures associated with Dravet syndrome, in the third quarter.

The Type A meeting was scheduled after the FDA issued a Refusal to File letter April 5, citing two issues: non-submission of non-clinical studies and an incorrect version of a clinical dataset within the application.

The FDA has agreed to the company's plan to resubmit the NDA without the inclusion of the new chronic toxicity studies requested by the agency. To address the second issue, Zogenix said it explained the incorrect dataset with root cause analysis.

Breakthrough Therapy Designation Rescinded

The FDA has cancelled the Breakthrough Designation for Fintelpa, as there are now two approved therapies for treating seizures associated with Dravet syndrome.

Zogenix said its candidate showed 57% more efficacy than one of the approved therapies, stiripentol.

Despite the cancellation of the breakthrough designation, the biotech said it hopes to obtain Priority Review status for its resubmitted NDA.

Zogenix shares were up 22.1% at $48.12 at the time of publication Thursday. 

Related Links:

The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO

Morphic Holding IPO: What You Need To Know

Posted-In: FinteplaBiotech News FDA Trading Ideas General Best of Benzinga

 

Related Articles (ZGNX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Mid-Morning Market Update: Markets Mostly Higher; Walgreens Earnings Top Views

10 Biggest Price Target Changes For Thursday